Cercare Medical A/S
Cercare Medical is based on +25 years of research in perfusion imaging and artificial intelligence. Our novel biomarkers provide unparalleled patient insights. We are bridging the gap between science and clinical practice. With our amazing customers, we use research to prove new ways for more accurate, more efficient and reliable care to help practitioners act with speed, insight and confidence – no matter the circumstances. Founded as a spin-out from Aarhus University, Denmark in 2013, by leading experts in perfusion imaging and AI, Cercare Medical’s solutions today are available all over the world.
Company details
Find locations served, office locations
- Business Type:
- Software vendor
- Industry Type:
- Medical Monitoring
- Market Focus:
- Globally (various continents)
- Year Founded:
- 2013
This company also provides solutions for other industrial applications.
Please, visit the following links for more info:
History
Cercare Medical’s Journey
Though founded in 2013, the history of Cercare Medical and our technology goes further back.
2021
Massachusetts General Hospital adapts Cercare Perfusion for neuroradiology research.
2021
Cercare Perfusion is implemented at Aarhus University Hospital for a pilot project to support assessment of brain tumors.
2021
FDA clearance achieved for Cercare Perfusion (MRI) – our AI-powered perfusion imaging solution.
2020
Launch on the Sectra Amplifier Store making Cercare Medical solutions accessible as compatible with Sectra PACS.
2019
CE Mark certification achieved for both Cercare Perfusion and Cercare Stroke.
2019
Study on robust estimation of hemo-dynamic parameters in traditional DCE-MRI models.
2018
Partnership established with Siemens Healthineers paving the way for making the Cercare Medical solutions accessible through the syngo.via OpenApps.
2017
Publication on reliable estimation of microvascular flow patterns in patients with disrupted blood-brain barrier using dynamic susceptibility contrast MRI.
2017
Study on biased visualisation of hypoperfused tissue by computed tomography due to short imaging duration: improved classification by image down-sampling and vascular models.
2016
Combat Stroke was renamed to Cercare Medical due to its growing solution portfolio.
2015
Perfusion MRI-derived indices of microvascular shunting and flow control correlate with tumor grade and outcome in patients with cerebral glioma.
2014
Publication on the reliable estimation of capillary transit time distributions using DSC-MRI.
2013
Company established under the previous name Combat Stroke as a spin-out from CFIN by Professor Kim Beuschau Mouridsen and Ph.D., MSc Mikkel Bo Hansen.
2006
Publication on automatic selection of arterial input function using cluster analysis.
2006
Publication on the Bayesian estimation of cerebral perfusion using a physiological model of the microvasculature.
2001
Kim Beuschau Mouridsen joined The Center of Functionally Integrative Neuroscience (CFIN) established at Aarhus University by Professors Leif Østergaard in 2000.
1996
Professor Leif Østergaard (Cercare Scientific Board Member) published the first ever paper on SVD in imaging which laid the foundation for advanced perfusion imaging.
Perfecting Perfusion Imaging
Through detailed image quality and deep insights, we optimise workflows and enable practitioners to make fast and confident decisions, when assessing brain CT and MR scans.
Our goal is to improve turnaround for hospitals and to help patients get the right treatment sooner.
We’re A Different Kind of Partner
Gain insight fast. Our advanced neuro-imaging technology delivers high-quality maps, enabling you to make reliable assessments of brain tissue status and viability.
Time is of the essence. Driven by AI, our solutions ensure fast turn-around, so you can make your resources matter.
Our technology adapts to yours. Multi-vendor compatibility and seamless integration via PACS and 3rd party viewers let you use what you already have.
Why our customers like Cercare
Full Automation
- Easy to use. Easy to integrate
- Modality and vendor agnostic
- Standardisation = highly repeatable
Reliable Results
- Imaging match the clinical symptoms
- Earlier disease detection with novel biomarkers
- Consistent results for longitudinal follow-ups